MyoKardia
Amgen reports positive results from landmark cardiovascular study
The study found significant reductions of major cardiovascular events in high-risk adults following treatment
Eli Lilly’s Mounjaro shown to provide cardiovascular protection in type 2 diabetes patients
Approximately 38.4 million people in the US are affected by diabetes
Novartis and ProFound enter cardiovascular disease collaboration worth $750m per target
The companies will aim to discover and develop new therapeutics for the group of disorders
Eli Lilly to expand cardiovascular disease pipeline with $1.3bn Verve acquisition
The deal will give Lilly access to Verve’s pipeline of gene editing medicines for atherosclerotic CVD
NewAmsterdam’s CETP inhibitor obicetrapib shows promise in Alzheimer’s sub-study
The trial was primarily designed to assess the LDL-C lowering efficacy of the candidate
Novo Nordisk’s GLP-1 drug Wegovy shows early protection against heart disease
Heart and circulatory diseases are responsible for more than 170,000 deaths in the UK every year
Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn
Cardiovascular diseases result in an estimated 17.9 million global deaths each year
AstraZeneca gains rights to CSPC’s lipid-lowering therapy in deal worth over $1.9bn
Dyslipidaemia is estimated to result in 2.6 million global deaths every year
Novartis announces positive late-stage results for Leqvio monotherapy in atherosclerotic CVD
Cardiovascular disease, including heart disease and stroke, is the leading cause of death globally
J&J to expand cardiovascular capabilities with V-Wave acquisition worth up to $1.7bn
The company’s medtech division will gain access to a cardiovascular implant device for heart failure
Johnson & Johnson to expand cardiovascular capabilities with $13.1bn Shockwave acquisition
Cardiovascular disease results in an estimated 17.9 million global deaths every year
Study reveals early menopause and higher CVD risk could be linked to cognitive decline
Approximately 733,040 people in Canada are estimated to be living with dementia